Merck & Co., Inc. (NYSE:MRK – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.12, Briefing.com reports. The company had revenue of $16.10 billion for the quarter, compared to analyst estimates of $15.87 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. Merck & Co., Inc.’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($2.06) earnings per share. Merck & Co., Inc. updated its FY 2024 guidance to 7.940-8.040 EPS and its FY24 guidance to $7.94-$8.04 EPS.
Merck & Co., Inc. Stock Performance
Shares of Merck & Co., Inc. stock traded down $2.79 on Wednesday, hitting $112.46. The stock had a trading volume of 16,202,075 shares, compared to its average volume of 8,533,465. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $134.63. The business’s 50 day moving average is $127.75 and its two-hundred day moving average is $126.66. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. The stock has a market cap of $284.84 billion, a price-to-earnings ratio of 124.77, a price-to-earnings-growth ratio of 1.66 and a beta of 0.38.
Merck & Co., Inc. Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.74%. The ex-dividend date is Monday, September 16th. Merck & Co., Inc.’s dividend payout ratio is currently 342.22%.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on Merck & Co., Inc.
Merck & Co., Inc. Company Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
See Also
- Five stocks we like better than Merck & Co., Inc.
- Why Are Stock Sectors Important to Successful Investing?
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- How to Calculate Return on Investment (ROI)
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- Are Penny Stocks a Good Fit for Your Portfolio?
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.